1.
J Allergy Clin Immunol Glob
; 2(1): 114-117, 2023 Feb.
Article
in English
| MEDLINE
| ID: mdl-37780100
ABSTRACT
We report on the successful treatment of a severe, recalcitrant dermatitis caused by CTLA-4 insufficiency with dupilumab, raising the possibility of a role of type 2 immunity in clinical conditions associated with CTLA-4 insufficiency.